AUROBAC THERAPEUTICS is a biopharmaceutical company established in 2022 through a strategic partnership between three global leaders in life sciences innovation: Boehringer Ingelheim, Evotec and bioMérieux. AUROBAC is dedicated to tackling urgent and unmet medical needs in the treatment of bacterial infections and their consequences in acute hospital settings, with a strong focus on the escalating threat of antimicrobial resistance (AMR).

AUROBAC is advancing a robust and diversified pipeline, headlined by ATX101, a potential first-in-class host-targeted therapy in development for the treatment of sepsis and septic shock (Phase 2 in preparation).

In parallel, AUROBAC has established multiple strategic partnerships to build a robust drug discovery engine designed to identify novel antimicrobial agents. This innovative platform aims to accelerate the development of novel treatments for acute respiratory infections, such as Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) caused by Gram-negative pathogens.